Litcius/Paper detail

Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics

Adam J. Nelson, Lisa A. Kaltenbach, Darren K. McGuire, Monica Levya, Hussein R. Al‐Khalidi, Laura Webb, Renato D. Lópes, Rodica Pop‐Busui, Matthew A. Cavender, Vanita R. Aroda, Melissa Magwire, Caroline R. Richardson, Ildiko Lingvay, Julienne K. Kirk, Ambarish Pandey, Tanya Gaynor, Jonathan Pak, Alana Washington, Çağrı Şenyücel, Jennifer B. Green, Christopher B. Granger, Neha J. Pagidipati

2024American Heart Journal7 citationsDOI

Topics & Concepts

MedicineDiscontinuationAtherosclerotic cardiovascular diseaseType 2 diabetesDiabetes mellitusDiseaseInternal medicineCardiologyIntensive care medicineEndocrinologyDiabetes Treatment and ManagementChronic Kidney Disease and DiabetesHyperglycemia and glycemic control in critically ill and hospitalized patients
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics | Litcius